Last scanned
Domain Age
Daily Visitors
Global Rank
Updated:
Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer and other malignant diseases
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
This website is hosted with 1&1 IONOS SE, which reserves the following IP addresses for apogenix.com: 217.160.0.147. Moreover, DNS used with this website include ns1037.ui-dns.biz, ns1037.ui-dns.com, ns1037.ui-dns.de, ns1037.ui-dns.org.
Last scanned
Domain Age
Daily Visitors
Global Rank
ns1037.ui-dns.biz
ns1037.ui-dns.com
ns1037.ui-dns.de
ns1037.ui-dns.org
{{value}}
1999-11-30
2023-11-30
IONOS SE
dataprivacyprotected@ionos.de
{{value}}
The registrar of apogenix.com is IONOS SE and the name expires on 2023-11-30. According to open source data, you can reach the owner at dataprivacyprotected@ionos.de but please make sure you have a good reason for unsolicited messages. Their country of residence is Germany.
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A